gsk3888550a
Vaccineexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
5
Phase 3
5
Phase 4
0
Earliest trial started Nov 15, 2018 (NCT03674177)
Timeline
Indications
Mechanism of action
- RSV F-proteinImmunity, active
RSV F-protein immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05229068 | Phase 3 | Mar 11, 2022 | GlaxoSmithKline |
| NCT05169905 | Phase 3 | Feb 2, 2022 | GlaxoSmithKline |
| NCT05045144 | Phase 3 | Sep 15, 2021 | GlaxoSmithKline |
| NCT04980391 | Phase 3 | Aug 3, 2021 | GlaxoSmithKline |
| NCT04605159 | Phase 3 | Nov 16, 2020 | GlaxoSmithKline |
| NCT03674177 | Phase 1 | Nov 15, 2018 | GlaxoSmithKline |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 6 | 6 | 2 | 2018 |
1 organizations
Page 1 / 1